Bavarian Nordic A-S: A Strong Start to 2025

COPENHAGEN, Denmark — Bavarian Nordic A/S (OMX: BAVA) has kicked off 2025 with impressive financial results, showcasing robust growth in its core segments. The biotechnology company, known for its pioneering work in cancer immunotherapy and vaccine production, reported a 62% increase in revenue for the first quarter, reaching DKK 1,347 million. This surge is primarily attributed to heightened demand in its Travel Health and Public Preparedness sectors.

The Travel Health segment saw a 52% revenue increase to DKK 680 million, driven by a surge in demand for rabies and tick-borne encephalitis (TBE) vaccines. Meanwhile, the Public Preparedness segment outperformed expectations with an 83% revenue jump to DKK 629 million, thanks to the timely fulfillment of several large orders.

Operating profit (EBITDA) for the quarter stood at DKK 420 million, translating to an EBITDA margin of 31%. This marks a significant improvement from the 3% margin reported in the same period last year. The company has maintained its financial guidance for the full year, projecting revenue between DKK 5,700 million and DKK 6,700 million, with an EBITDA margin of 26-30%.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, expressed optimism about the company’s trajectory: “A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our expectations.”

Upcoming Investor Conference

In addition to its financial achievements, Bavarian Nordic is set to participate in Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025. The event will feature live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Bavarian Nordic will present at 8:00 AM US Eastern Standard Time, providing an opportunity for investors and analysts to gain deeper insights into the company’s strategies and future prospects.

The conference, which includes representatives from companies across China, Hong Kong, the Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom, is open to all investors and analysts. There is no fee to attend, and pre-registration is suggested.

As Bavarian Nordic continues to navigate the competitive landscape of the biotechnology sector, its strong start to the year and strategic engagements with the investment community underscore its commitment to addressing significant health challenges and delivering innovative solutions.